Mesa Laboratories (MLAB) Lays Out First Full-Year Revenue Forecast as Q2 Strengths Align with SDC Momentum

Lakewood, Colorado — November 9, 2026

Snapshot: the quarter in numbers

Mesa Laboratories, Inc. (NASDAQ: MLAB) reported its second quarter (2Q27) ended September 30, 2026, with a revenue print of $62.336 million, up 2.6% from the prior year. The release includes the usual tolls you’d expect—non-GAAP measures, organic growth, and EBITDA—while deliberately withholding an EPS figure and an explicit EPS consensus. In other words, if you’re checking for a classic “EPS surprise” versus a consensus, the data won’t deliver a fireworks show on that metric. Still, the company issued its first full-year revenue forecast, which matters a lot more than a one-quarter earnings per share blip.

Revenues of $62.336 million, up 2.6% year over year; non-GAAP organic and constant-currency organic revenues grew 2.6% and 3.1%, respectively.
Non-GAAP revenues excluding Clinical Genomics up 5.2% (5.8% in constant currency) to $52.171 million; for the first six months, up 3.2% (3.3% CC) to $102.020 million.
Segment momentum—Sterilization and Disinfection Control (SDC) revenues up 14.6% to $25.342 million; last-twelve-months total for the division rises to $103.897 million (an 8.5% increase).
Profitability—Operating income up 77.6% to $8.388 million; net income up 75.3% to $4.341 million.
Non-GAAP EBITDA up 21.1% to $17.317 million (28.0% of revenues, as the slide notes 27.8% of revenues).
Leverage and cash—debt repayment of $11.406 million reduced the total net leverage ratio to 1.75x.
Guidance—the company issued its full-year fiscal 2027 forecast: revenues of $250 million to $255 million and adjusted EBITDA of $66 million to $68 million.

Business mix: four divisions and a focus on execution

Mesa operates across four divisions: Sterilization and Disinfection Control (SDC), Biopharmaceutical Development (BPD), Calibration Solutions (CS), and Clinical Genomics (CG). The commentary attached to the quarter underscores SDC as a driver of the quarter’s strength, while CG and BPD are watching external headwinds—especially export-control processing delays that have intermittently weighed on performance. The non-GAAP revenue line excluding CG rose nicely, suggesting a more resilient core beyond the CG segment’s near-term friction.

Leadership tone and strategic posture

Executive commentary centers on durability and discipline. Dr. Siddhartha Kadia, Mesa’s President and CEO, frames the company as a portfolio of durable, regulation-embedded franchises with real and growing earnings power. CFO John Sakys adds a pragmatic note: debt repayment and leverage reduction are a statement about balance-sheet health, not a one-quarter mirage funded by cost-cutting. The overarching subtext: the first full-year revenue forecast aims to anchor expectations in a credible plan rather than chase quarterly fireworks.

The implications for the sector and what to watch next

In the broader life sciences tools universe, Mesa’s progress on forecasting—specifically the revenue forecast rather than trailing quarterly results—may recalibrate how investors judge sustainability. If SDC’s growth persists and CG exposure to export-control delays eases, peers could gravitate toward reinforcing recurring-revenue elements and service-based margins to stabilize earnings power.

On the EPS side, the absence of a disclosed EPS figure or consensus means any potential earnings-per-share interpretation rests on the margin trajectory and leverage improvement rather than a single-quarter beat or miss. A favorable EBITDA margin trajectory and debt reduction could portend higher earnings quality for the sector, even if near-term per-share metrics stay murkier. For rival makers of sterilization, disinfection, and related life-science tools, Mesa’s approach signals an emphasis on execution discipline and long-run profitability—traits investors tend to reward when the economy slows or funding becomes more selective.

Bottom line: a measured advance with a credible forecast

Mesa’s Q2 results reveal a company leaning into steady growth, margin leverage, and a clear revenue forecast that anchors expectations going forward. The 2Q27 narrative centers less on a volatile earnings surprise and more on a credible plan to grow revenue and shrink leverage while navigating the CG segment’s export-control dynamics. For investors, the key takeaway is that MLAB could be laying the groundwork for a more durable earnings trajectory, one that may translate into a more predictable EPS path if the company can convert EBITDA gains into per-share profitability. For peers, the message is to combine robust core strengths with financial discipline—because in life sciences tooling, credibility on the revenue forecast often beats a dazzling but unsustainable quarterly splash.